thalidomide has been researched along with Smith-Magenis Syndrome in 4 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Smith-Magenis Syndrome: Complex neurobehavioral disorder characterized by distinctive facial features (FACIES), developmental delay and INTELLECTUAL DISABILITY. Behavioral phenotypes include sleep disturbance, maladaptive, self-injurious and attention-seeking behaviors. The sleep disturbance is linked to an abnormal circadian secretion pattern of MELATONIN. The syndrome is associated with de novo deletion or mutation and HAPLOINSUFFICIENCY of the retinoic acid-induced 1 protein on chromosome 17p11.2.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Biran, N | 1 |
| Jagannath, S | 1 |
| Chari, A | 1 |
| Strati, P | 1 |
| Keating, MJ | 1 |
| O'Brien, SM | 1 |
| Ferrajoli, A | 1 |
| Burger, J | 1 |
| Faderl, S | 1 |
| Tambaro, FP | 1 |
| Jain, N | 1 |
| Wierda, WG | 1 |
| Sun, C | 1 |
| Wiestner, A | 1 |
| Lee, J | 1 |
| Smith, D | 1 |
| Rabin, N | 1 |
| Tobias, J | 1 |
| Yong, K | 1 |
2 reviews available for thalidomide and Smith-Magenis Syndrome
| Article | Year |
|---|---|
Risk stratification in multiple myeloma, part 2: the significance of genetic risk factors in the era of currently available therapies.
Topics: Angiogenesis Inhibitors; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 13; Chr | 2013 |
Prognosis and therapy of chronic lymphocytic leukemia and small lymphocytic lymphoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Biomarkers, Tumor; Chromosome Deletion; Chromosomes, | 2015 |
2 other studies available for thalidomide and Smith-Magenis Syndrome
| Article | Year |
|---|---|
Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2014 |
17P deleted multiple myeloma presenting with intracranial disease: durable remission after tailored management.
Topics: Autografts; Bortezomib; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 17; Consolida | 2016 |